Strides Pharma Global Pte Ltd has received approval from the US health regulator for Prednisone tablets as confirmed by Drug firm Strides Pharma Science on Friday.
These tables are prescribed for a variety of conditions, including allergies, respiratory illness and arthritis.
The approved product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Deltasone tablets, 10 mg and 20 mg, of Pharmacia and Upjohn Co.
Moreover, prednisone belongs to a class of drugs known as corticosteroids which is used as an anti-inflammatory or an immuno-suppressant medication.
The product will be marketed by Strides Pharma Inc. in the US market and manufactured at the company’s facility at Bengaluru.
Shares of Strides Pharma Science were trading 2.81 per cent higher at Rs 890.10 a piece on BSE.
Moreover, the Company has 127 cumulative ANDA filings with USFDA currently.
Also, only 98 ANDAs have been approved so far and 29 are still pending for approval.
According to IQVIA MAT December 2020 data, the US market for Prednisone Tablets USP, 10 mg and 20 mg is approximately of US$ 60 Million.
It is to be noted that tetracycline hydrochloride capsule is used when penicillin or another antibiotic cannot be used to treat serious infections such as Anthrax, Listeria etc.
Infact, the approved medicine also slows down HIV spread and prescribed along with other medications to treat adults and children.
Check all the recent news updates and share market updates